1. Home
  2. TNGX vs FAX Comparison

TNGX vs FAX Comparison

Compare TNGX & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • FAX
  • Stock Information
  • Founded
  • TNGX 2014
  • FAX 1986
  • Country
  • TNGX United States
  • FAX United States
  • Employees
  • TNGX N/A
  • FAX N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • FAX Investment Managers
  • Sector
  • TNGX Health Care
  • FAX Finance
  • Exchange
  • TNGX Nasdaq
  • FAX Nasdaq
  • Market Cap
  • TNGX 723.2M
  • FAX 672.5M
  • IPO Year
  • TNGX N/A
  • FAX N/A
  • Fundamental
  • Price
  • TNGX $7.58
  • FAX $15.79
  • Analyst Decision
  • TNGX Strong Buy
  • FAX
  • Analyst Count
  • TNGX 6
  • FAX 0
  • Target Price
  • TNGX $10.00
  • FAX N/A
  • AVG Volume (30 Days)
  • TNGX 2.6M
  • FAX 833.6K
  • Earning Date
  • TNGX 11-05-2025
  • FAX 01-01-0001
  • Dividend Yield
  • TNGX N/A
  • FAX 12.09%
  • EPS Growth
  • TNGX N/A
  • FAX N/A
  • EPS
  • TNGX N/A
  • FAX N/A
  • Revenue
  • TNGX $24,296,000.00
  • FAX N/A
  • Revenue This Year
  • TNGX $20.42
  • FAX N/A
  • Revenue Next Year
  • TNGX N/A
  • FAX N/A
  • P/E Ratio
  • TNGX N/A
  • FAX N/A
  • Revenue Growth
  • TNGX N/A
  • FAX N/A
  • 52 Week Low
  • TNGX $1.03
  • FAX $2.33
  • 52 Week High
  • TNGX $8.80
  • FAX $2.84
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 51.87
  • FAX 29.87
  • Support Level
  • TNGX $7.66
  • FAX $16.15
  • Resistance Level
  • TNGX $8.80
  • FAX $16.68
  • Average True Range (ATR)
  • TNGX 0.51
  • FAX 0.23
  • MACD
  • TNGX -0.04
  • FAX -0.09
  • Stochastic Oscillator
  • TNGX 33.70
  • FAX 7.50

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

Share on Social Networks: